Rivastigmine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Rivastigmine: From Alzheimer’s Disease to Glaucoma
One-Sentence Summary
Rivastigmine is a selective acetylcholinesterase (AChE) inhibitor established for Alzheimer’s disease dementia. The TxGNN model predicts it may be effective for Glaucoma, with 0 clinical trials and 3 publications currently supporting this direction — all preclinical/mechanistic in nature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Alzheimer’s disease dementia (inferred from literature evidence in this pack; no EU/TFDA license record exists) |
| Predicted New Indication | Glaucoma |
| TxGNN Prediction Score | 99.27% |
| Evidence Level | L4 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data from DrugBank is currently a data gap. Based on the literature evidence collected in this pack, Rivastigmine is a selective carbamate-type acetylcholinesterase (AChE) inhibitor, with established efficacy in Alzheimer’s disease dementia by increasing central acetylcholine levels to compensate for cholinergic deficit.
The link to glaucoma comes from a separate branch of AChE pharmacology: non-selective AChE inhibitors have long been known as ocular hypotensive agents, and cholinergic signaling via muscarinic receptors (M3R) in the trabecular meshwork directly regulates intraocular pressure (IOP) (PMID 39130374). A direct animal study (PMID 10673128) tested topical rivastigmine in rabbits and found it lowered IOP over an 8-hour observation period, despite rivastigmine’s selectivity for a CNS-predominant AChE isoform.
Mechanistically, this suggests that even a CNS-selective AChE inhibitor can produce a local IOP-lowering effect when applied topically, without necessarily triggering the systemic cholinergic side effects associated with non-selective agents (PMID 27967267). This is a plausible but early-stage mechanistic hypothesis rather than a clinically validated pathway.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10673128 | 2000 | Preclinical (animal study) | J Ocul Pharmacol Ther | Topical rivastigmine lowered intraocular pressure in normotensive rabbits, monitored hourly over 8 hours |
| 39130374 | 2024 | Review | Front Mol Biosci | Reviews cholinergic/muscarinic (M3R) regulation of IOP via the trabecular meshwork; notes systemic cholinergic side effects limit current M3R agonists |
| 27967267 | 2017 | Review (patent literature) | Expert Opin Ther Pat | Notes mild AChE inhibition has therapeutic relevance in Alzheimer’s disease, myasthenia gravis, and glaucoma |
EU Market Information
Rivastigmine currently has no EU marketing authorization record in this evidence pack (market status: Not marketed / Not marketed, 0 licenses).
Safety Considerations
Please refer to the SmPC for safety information.
(Note: TFDA warnings/contraindications and full DrugBank DDI data are currently unavailable — see Next Steps below.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for the glaucoma indication is limited to one 2000-era animal study and two narrative reviews (Evidence Level L4) — no clinical trials or RCTs exist. Combined with the drug’s current non-marketed status in the EU and a blocking data gap on TFDA safety labeling, the candidate is not yet ready to advance to safety screening (S1).
To proceed, the following is needed:
- TFDA label (warnings/contraindications) — blocking gap (DG001); remediation: download PDF from TFDA official site and parse
- Confirmed MOA data — high-priority gap (DG002); remediation: query DrugBank API
- Identification of any registered/planned clinical trials evaluating rivastigmine (topical or systemic) for IOP reduction or glaucoma
- Confirmation of current global marketing/regulatory status for rivastigmine formulations suitable for ocular use
- Preclinical-to-clinical translation data (topical dose, ocular tolerability, route feasibility)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.